Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Ysios Capital
Deal Size : $56.6 million
Deal Type : Series A Financing
Details : The proceeds from the financing, the largest Series A round for a Spanish biotech company, will enable SpliceBio to build a pipeline of Protein Splicing gene therapy programs, while advancing the lead program in Stargardt disease to the clinic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 16, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Ysios Capital
Deal Size : $56.6 million
Deal Type : Series A Financing